GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cargo Therapeutics Inc (NAS:CRGX) » Definitions » EV-to-FCF

Cargo Therapeutics (Cargo Therapeutics) EV-to-FCF : (As of May. 09, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cargo Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cargo Therapeutics's Enterprise Value is $418.45 Mil. Cargo Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Cargo Therapeutics's EV-to-FCF for today is .

The historical rank and industry rank for Cargo Therapeutics's EV-to-FCF or its related term are showing as below:

CRGX' s EV-to-FCF Range Over the Past 10 Years
Min: -39.27   Med: 0   Max: 0
Current: -4.64

CRGX's EV-to-FCF is ranked worse than
100% of 380 companies
in the Biotechnology industry
Industry Median: 5.98 vs CRGX: -4.64

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-09), Cargo Therapeutics's stock price is $20.38. Cargo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.695. Therefore, Cargo Therapeutics's PE Ratio for today is At Loss.


Cargo Therapeutics EV-to-FCF Historical Data

The historical data trend for Cargo Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cargo Therapeutics EV-to-FCF Chart

Cargo Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
EV-to-FCF
- - -6.40

Cargo Therapeutics Quarterly Data
Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial - - - - -6.40

Competitive Comparison of Cargo Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Cargo Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cargo Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cargo Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Cargo Therapeutics's EV-to-FCF falls into.



Cargo Therapeutics EV-to-FCF Calculation

Cargo Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=418.449/0
=

Cargo Therapeutics's current Enterprise Value is $418.45 Mil.
Cargo Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cargo Therapeutics  (NAS:CRGX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Cargo Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=20.38/-1.695
=At Loss

Cargo Therapeutics's share price for today is $20.38.
Cargo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.695.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Cargo Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Cargo Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cargo Therapeutics (Cargo Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
1900 Alameda De Las Pulgas, Suite 350, San Mateo, CA, USA, 94403
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing strategy are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. Their lead program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

Cargo Therapeutics (Cargo Therapeutics) Headlines